Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: To investigate the prognosis of longitudinal health-related quality of life (HRQOL) during concurrent chemoradiotherapy (CCRT) on survival outcomes in patients with advanced nasopharyngeal carcinoma (NPC).
Methods: During 2012-2014, 145 adult NPC patients with stage II-IVb NPC were investigated weekly using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORCT QLQ-C30) during their CCRT period. The effects of longitudinal trends of HRQOL on survival outcomes were estimated using joint modeling, and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were reported as a 10-point increase in HRQOL scores.
Results: After a median follow-up of 83.4 months, the multivariable models showed significant associations of longitudinal increasing scores in fatigue and appetite loss during the CCRT period with distant metastasis-free survival: 10-point increases in scores of fatigue and appetite loss domains during CCRT period were significantly associated with 75% (HR: 1.75, 95% CI: 1.01, 3.02; p = 0.047) and 59% (HR: 1.59, 95% CI: 1.09, 2.59; p = 0.018) increase in the risk of distant metastasis, respectively. The prognostic effects of the longitudinal HRQOL trend on overall survival and progress-free survival were statistically non-significant.
Conclusion: Increases in fatigue and appetite loss of HRQOL during the CCRT period are significantly associated with high risks of distant metastasis in advanced NPC patients. Nutritional support and psychological intervention are warranted for NPC patients during the treatment period.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11414072 | PMC |
| http://dx.doi.org/10.1186/s13014-024-02473-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Short-course PD-1 blockade in locally advanced nasopharyngeal carcinoma: a phase II randomized trial protocol (Tori-013).
Front Immunol
September 2025
Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
While immunotherapy has demonstrated encouraging efficacy in locally advanced nasopharyngeal carcinoma (LANPC), the optimal combination modalities and treatment duration remain undetermined. In the present study, we developed a clinical trial protocol to evaluate shortened period of immunotherapy could enhance the efficacy of LANPC. This open-label, randomized, single-blind, multicenter phase II trial (Tori-013) investigates the efficacy and safety of toripalimab (anti-PD-1 monoclonal antibody) combined with induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in patients with stage III/IVa nasopharyngeal carcinoma (NPC).
View Article and Find Full Text PDFIncorporation of oXiris Bioabsorbent Filter into CRRT in the treatment of severe abdominal infections and analysis of associated risk factors for early off-machine.
Front Public Health
August 2025
Department of Emergency, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Introduction: This study aims to evaluate the impact of oXiris continuous renal-replacement therapy (CRRT) on the prognosis of patients with severe intra-abdominal infections (IAIs) and to analyze potential risk factors for early off-machine of oXiris CRRT during treatment.
Methods: A total of 49 patients with severe abdominal infections admitted to the intensive care unit of the First Affiliated Hospital of Fujian Medical University from October 2020 to October 2023 were retrospectively analyzed. The patients were divided into a conventional group and an oXiris group.
Concurrent vs. sequential chemoradiotherapy: a survival boost for lung cancer patients.
Biomed Eng Online
May 2025
Departerment of Oncology, Gaoxin Branch of the First Affiliated Hospital of Nanchang University, No. 7889 Changdong Avenue, High-tech Zone, Nanchang, 330000, Jiangxi, China.
Objective: To investigate the clinical efficacy, incidence of radiation pneumonitis, and impact on lung function of sequential chemoradiotherapy (SCRT) and concurrent chemoradiotherapy (CCRT) in the treatment of lung cancer.
Method: From January 2020 to December 2022, 158 patients with non-small cell lung cancer (NSCLC) were admitted to our hospital and chosen as the study subjects. Their clinical data were analyzed retrospectively and organized into a control group (n = 78, received SCRT) and an observation group (n = 80, received CCRT).
Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival.
Lung Cancer
June 2025
Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden. Electronic address:
Introduction: Stage III non-small cell lung cancer (NSCLC) is a heterogeneous group and identification of subgroups with differential treatment responses is crucial. Addition of durvalumab to concurrent chemoradiotherapy (cCRT) has previously been shown to improve survival outcomes. Meanwhile, subgroups harboring KRAS mutations have been shown to have worse prognosis.
View Article and Find Full Text PDFPhase II Study to Evaluate the Safety and Efficacy of Neoadjuvant Chemotherapy with Weekly Paclitaxel and Carboplatin Followed by Radical Chemoradiation in Locally Advanced Cervical Cancer in Egyptian Population.
Asian Pac J Cancer Prev
April 2025
Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University, El Qalybia, Cairo, Egypt.
Background: Since 1999, platinum based chemoradiation (CRT) is the standard treatment for locally advanced cervical cancer patients, but the estimated increase in overall survival (OS) over a 5-year period was only 6% in patients treated with CRT versus radiotherapy alone.There have been no additional developments in the treatment of locally advanced cervical cancer(LACC) patients since CRT introduction and approximately 30-40% of those patients failed to achieve complete response to CRT. Therefore, alternative approaches are needed to improve the outcome for such patients.
View Article and Find Full Text PDF